The peroxisome proliferator activated receptor gamma (PPARg) is a ligand-activated transcription factor that regulates growth and differentiation within normal prostate and prostate cancers. However the factors that control PPARg within the prostate cancers have not been characterized. The goal of this study was to examine whether the androgen receptor (AR) regulates PPARg expression and function within human prostate cancer cells. qRT-PCR and Western blot analyses revealed nanomolar concentrations of the AR agonist dihydrotestosterone (DHT) decrease PPARg mRNA and protein within the castration-resistant, AR-positive C4-2 and VCaP human prostate cancer cell lines. The AR antagonists bicalutamide and enzalutamide blocked the ability of DHT to reduce PPARg levels. In addition, siRNA mediated knockdown of AR increased PPARg protein levels and ligand-induced PPARg transcriptional activity within the C4-2 cell line. Furthermore, proteasome inhibitors that interfere with AR function increased the level of basal PPARg and prevented the DHT-mediated suppression of PPARg. These data suggest that AR normally functions to suppress PPARg expression within AR-positive prostate cancer cells. To determine whether increases in AR protein would influence PPARg expression and activity, we used lipofectamine-based transfections to overexpress AR within the AR-null PC-3 cells. The addition of AR to PC-3 cells did not significantly alter PPARg protein levels. However, the ability of the PPARg ligand rosiglitazone to induce activation of a PPARg-driven luciferase reporter and induce expression of FABP4 was suppressed in AR-positive PC-3 cells. Together, these data indicate AR serves as a key modulator of PPARg expression and function within prostate tumors.
The peroxisome proliferator activated receptor gamma (PPARg) is a member of the nuclear receptor superfamily that is activated by prostaglandins and several synthetic compounds. Upon binding ligand, PPARg associates with regions of genomic DNA known as PPAR response elements (PPREs) as part of a heterodimer with the retinoid X receptor (RXR). This association results in the recruitment of coactivators, such as PPARg coactivator 1 (PGC1), steroid receptor coactivator-1 (SRC-1) and CBP/p300, to DNA and alterations in gene expression. While high levels of PPARg are expressed within adipose tissue, PPARg is also present within the normal prostate. Within the prostate epithelium PPARg functions as a tumor suppressor, for conditional knockout of PPARg within mouse epithelial cells results in the development of prostatic intraepithelial neoplasia (PIN), a precursor of prostate cancer (Jiang et al., 2010a) . Loss of PPARg also increases the level of autophagy within the mouse prostate (Jiang et al., 2010a,b) . Furthermore, studies by DW Strand et al. revealed knockdown of two PPARg isoforms (PPARg1 and PPARg2) within the BHPrE normal human prostate cell line results in low expression of prostate differentiation markers (Strand et al., 2013) . Taken together these data suggest PPARg is a key regulator of prostatic differentiation and cell survival in normal prostatic tissue. PPARg protein and mRNA have been detected within human prostate cancer cell lines and prostate tumors (Butler et al., 2000; Segawa et al., 2002; Sabichi et al., 2004; Subbarayan et al., 2004; Lyles et al., 2009; Moss et al., 2010) . However, the significance of PPARg expression within prostate cancers is not fully understood. In addition, the factors that control PPARg levels and function within human prostate cancer cells have not been characterized.
The androgen receptor (AR) is also a member of the nuclear receptor superfamily that plays a critical role in the development and differentiation of normal prostate and the progression of prostate cancer. Activation of AR via the androgens testosterone and dihydrotestosterone (DHT) promotes growth of early stage prostate cancers. For this reason the reduction of circulating androgens via castration and other types of androgen deprivation therapy (ADT) is the standard treatment for patients with advanced, metastatic prostate cancer. Unfortunately, castration-resistant forms of the prostate tumor develop approximately 18-24 months after the start of ADT (Santen, 1992) . Although castration-resistant tumors don't require androgens for tumor growth, they continue to express active forms of AR. Multiple factors appear to contribute to the increased level of AR activation within castration-resistant prostate cancers. These include amplifications and mutations of the AR gene, the expression of constitutively active N-terminal AR variants, ligand-independent activation of AR by growth factors and cytokines, and local production of androgens within prostate tumors (Knudsen and Penning, 2010) . Furthermore, AR is still a major driver of tumor growth within these recurrent castration resistant prostate cancers. Data from ChIP-seq and expression profiling studies indicate AR regulates proteins that are involved in cell cycle progression, biosynthetic pathways and cellular metabolism within human prostate cancer cells (Wang et al., 2009; Massie et al., 2011) . However, the extent to which alterations in these gene products contribute to the promotion of tumor growth by AR is still unclear.
Interactions between the AR and PPARg signaling pathways occur within adipose tissue and influence the process of adipogenesis. Data from R. Singh and colleagues revealed activation of AR by testosterone and DHT not only suppresses adipocyte differentiation but also decreases PPARg mRNA and protein levels in mouse 3T3-L1 preadipocytes. Furthermore, DHT produced a similar reduction in PPARg2 mRNA and protein levels within mouse pluripotent C3H10T1/2 cells (Singh et al., 2003) . It is not known if PPARg and AR signaling pathways interact in human prostate, and whether this interaction influences the biology of normal or diseased prostate. The goal of the present study was to determine if AR might influence PPARg function within human prostate cancer cells. Our data reveal that AR suppresses PPARg transcriptional activity in prostate cancer cells, and that in AR-positive prostate cancer cells this suppression is due in part to AR-mediated reductions in PPARg expression.
Materials and Methods Materials
DMEM low glucose media, DMEM high glucose media, Hams' F-12 media, DMEM/F-12 media (1:1), penicillin/streptomycin solution and phosphate buffered saline (PBS) were purchased from Invitrogen (Carlsbad, CA). The media additives d-biotin, adenine hemisulfate, insulin solution, apo-transferrin, and Nuclei EZ Prep kit were purchased from Sigma-Aldrich (St. Louis, MO). Fetal bovine serum (FBS) was obtained from HyClone (Logan, UT). Charcoal stripped FBS (CSS) was prepared within our laboratory or purchased from Invitrogen (Carlsbad, CA). Zapoglobin and Isoton II were purchased from Beckman Coulter Inc. (Fullerton, CA). Rabbit anti-mouse IgG secondary antibody was obtained from Zymed Laboratories, Inc. Both horseradish peroxidaseconjugated donkey anti-rabbit and sheep anti-mouse antibodies were purchased from GE Healthcare Biosciences (Pittsburg, PA). All tissue culture plasticware and additional chemicals were purchased from Fisher Scientific (Suwanee, GA).
Drugs
The PPARg agonist rosiglitazone was purchased from Cayman Chemical (Ann Arbor, MI). Stock solutions of rosiglitazone were prepared by diluting the compound in 100% DMSO and stored at À20°C. The proteasome inhibitor MG132 was purchased from Sigma-Aldrich. Stock solutions of MG132 were diluted in DMSO and stored at À20°C. The AR antagonist bicalutamide was purchased from Tocris Bioscience (Minneapolis, MN) and stored at À20°C as a stock solution in 100% DMSO. The more potent AR antagonist enzalutamide, which was purchased from Selleck Chemicals (Houston, TX), was diluted in 100% ethanol (EtOH) and stored at À20°C.
Cell lines
The C4-2 cell line was purchased from ViroMed Laboratories (Burlington, NC) and grown in T medium (80% DMEM low glucose medium, 20% Hams' F12 medium, 5% heat inactivated FBS, 1% penicillin/streptomycin, 0.244 mg/ml d-biotin, 25 mg/ml adenine hemisulfate, 5 mg/ml insulin and 5 mg/ml apotransferrin). The PC-3 cell line, which was purchased from ATCC (Manassas, VA), was grown in DMEM-F12 medium supplemented with 10% FBS and 1% penicillin/streptomycin. The VCaP cell line was purchased from ATCC and grown in DMEM high glucose medium supplemented with 10% FBS and 1% penicillin/streptomycin. Each cell line was maintained in an incubator with a 5% CO 2 atmosphere at 37°C.
Western blot analysis
To measure the effect of DHT on PPARg protein levels, C4-2 and VCaP cells were plated at a density of 600,000-750,000 cells per 10 cm dish in either T media supplemented with 5% CSS (C4-2 cells) or DMEM high glucose media supplemented with 10% CSS (VCaP cells). The cells were then treated with ethanol vehicle (EtOH) or the indicated concentrations of dihydrotestosterone (DHT) for up to 24 h. For experiments involving proteasome inhibitors or AR antagonists, the cells were pretreated with DMSO vehicle, MG132, enzalutamide or bicalutamide prior to the addition of EtOH or DHT. Following drug exposure, cells were lysed using the Sigma-Aldrich Nuclei EZ Prep Nuclei Isolation Kit to prepare nuclear extracts or RIPA buffer (Thermo Scientific, Pittsburg, PA) to prepare whole cell extracts. Protein concentrations for each sample were calculated using the Bradford protein assay (BioRad, Hercules, CA). Equal amounts of protein from each extract were separated on SDS-PAGE gels and transferred to a nitrocellulose membrane. Membrane blots were then blocked in TBST (1Â TBS, 0.1% Tween 20) containing 1% non-fat powdered milk and incubated with primary antibody diluted in the blocking solution overnight at 4°C. The primary antibodies used were the PPARg rabbit polyclonal antibody (clone H-100, Santa Cruz Biotechnology, Santa Cruz, CA; 1:200) and the AR mouse monoclonal antibody (clone AR 441, Lab Vision Corporation, Fremont, CA; 1:400). Following exposure to primary antibody, the blots were washed in blocking buffer and then incubated with either a donkey anti-rabbit or sheep anti-mouse secondary antibody conjugated to horseradish peroxidase. Proteins were then visualized using the Pierce Enzyme-Linked Chemiluminescence (ECL) Western Blotting Substrate (Thermo Scientific). ECL images were captured using either X-ray film or the Carestream Gel Logic 4000 imaging system. Blots containing nuclear extracts were stripped and reprobed with a rabbit polyclonal topoisomerase I antibody (clone H-300, Santa Cruz Biotechnology; 1:400). Blots containing whole cell lysates were reprobed with an actin mouse monoclonal antibody (Chemicon International, Temecula, CA; 1:10,000) or alpha tubulin antibody (Santa Cruz, Biotechnology, 1:200) to confirm equal loading of the gel.
qRT-PCR analysis
To measure basal levels of PPARg mRNA, untreated cells were incubated in FBS-containing media for 72 h. Total RNA was then isolated from each cell line with the Qiagen RNeasy Kit or Trizol reagent according to the manufacturer's protocol. For each sample the iScript cDNA Synthesis Kit (BioRad) was used to synthesize cDNA from 1 mg of total RNA. The cDNA was then amplified by quantitative PCR using a reaction involving iQ SYBR Green Supermix reagent (BioRad). This PCR reaction consisted of an initial denaturation step (3 min at 95°C) and 40 cycles of PCR (95°C for 30 sec, 55°C for 30 sec and 72°C for 30 sec). The Qiagen PPARg primer set (HsPPARG_1_SG Quantitect Primer Cat. #ATT00029841), PPARg2 Forward (GACCACTCCCACTCCTT TGA) and Reverse (5 0 -TCCATGCTGTTATGGGTGAA) primers, as well as the 18S Forward (5 0 -ATC AAC TTT CGA TGG TAG TCG-3 0 ) and 18S Reverse (5 0 -TCC TTG GAT GTG GTA GCG-3 0 ) primers were used to detect the presence of total PPARg mRNA, PPARg2 mRNA and 18S rRNA. The DDCt algorithm was used to calculate the relative amounts of PPARg mRNA and 18S rRNA in each sample. The level of PPARg mRNA (total PPARg or PPARg2) was then normalized to 18S rRNA levels.
To examine the effect of DHT on PPARg mRNA levels, C4-2 and VCaP cells were plated in media supplemented with either 5% CSS (C4-2 cells) or 10% CSS (VCaP). The cells were then treated with EtOH or the indicated concentrations of DHT for 0-24 h. Total RNA was isolated using the Qiagen RNeasy Kit or Trizol reagent according to the manufacturer's instructions. The amount of total PPARg and 18S rRNA in each total RNA samples was then measured as described above.
To measure mRNA levels of the PPARg target gene adipose fatty acid binding protein (FABP4), total RNA was extracted from treated cells using the Trizol reagent. The iScript cDNA Synthesis Kit was then used to synthesize cDNA from 1 mg of total RNA. qPCR was performed using the 18S primers described above and FABP4-specific Forward (5 0 -TCAACGTCCCTTGGCTTATGC-3 0 ) and reverse (5 0 -TCAGTGTGAATGGGGATGTGA-3 0 ) primers. The DDCt algorithm was used to calculate the relative amounts of FABP4 mRNA and 18S rRNA in each sample.
siRNA studies
To determine how loss of AR affects PPARg expression, C4-2 cells were first transfected with an AR SMARTpool siRNA or a nonspecific SMARTpool siRNA (GE Dharmacon, Lafayette, CO) via electroporation. Following transfection, the cells were placed in RPMI 1640 media containing 5% FBS at a density of 260,000 cells/well of a 6 well plate and allowed to recover for 48 h. Nuclear extracts were then isolated from transfected cells. Western blot analysis was then performed as described above to detect the level of AR and PPARg in each cell extract. Blots were stripped and reprobed with a rabbit polyclonal topoisomerase I antibody (clone H-300, Santa Cruz Biotechnology; 1:400) to confirm equal loading of the gel.
To determine whether AR loss affects PPARg-driven luciferase activity, C4-2 cells were transfected with 20 mg PPRE3-luciferase, 2 mg CMV b-galactosidase plasmid, and 20 mM of either nonspecific control SMARTpool siRNA or AR SMARTpool siRNA via electroporation ($5 million cells per transfection). Following transfection, the cells were placed in RPMI 1640 media containing 5% FBS and allowed to recover for 24 h. After the recovery period the cells were treated for 24 h with either DMSO vehicle or 40 mM of the PPARg agonist rosiglitazone. The luciferase activity in treated cells was measured using the Luciferase Assay System kit from Promega (Madison, WI) and normalized to b-galactosidase activity. In parallel wells, transfected cells were lysed using RIPA buffer. The level of AR and tubulin protein in each whole cell lysate was then measured by Western blot analysis.
To assess how loss of p65 NFkB affects androgen-induced suppression of PPARg, C4-2 cells were first transfected with a p65 siRNA SMARTpool siRNA (Dharmacon) or a non-targeting control SMARTpool siRNA via electroporation and allowed to recover for 48 h. The cells were then placed in media containing 5% CSS and treated for 24 h with either EtOH or 1 nM DHT. Following treatment, the level of p65 NFkB, PPARg, AR and actin protein in whole cell extracts from treated cells was measured by Western blot analysis. 
AR overexpression studies
To study the effect of AR overexpression on PPARg transcriptional activity, PC-3 cells were plated at a density of 75,000 cells/well in a 6 well plate. They were next transfected with 500 ng PPRE3-luciferase reporter plasmid, 500 ng CMV b-galactosidase plasmid, and 1 mg of either PCR-3.1 AR or PCR3.1 expression vector using Lipofectamine (Invitrogen). Following transfection, the cells were placed in DMEM/F12 media containing 10% FBS and allowed to recover for 24 h. After the recovery period the cells were treated with either DMSO or different concentrations of rosiglitazone (10-40 mM) for 24 h. The luciferase activity in treated cells was measured using the Luciferase Assay System and normalized to b-galactosidase activity. Western blot analysis was performed as previously described to measure the level of AR, PPARg, and actin protein in transfected cells.
To analyze the effect of AR overexpression on the PPARg target gene FABP4, PC-3 cells were plated at a density of 75,000 cells/well in a 6 well plate. Lipofectamine was then used to transfect the cells with 1 mg of either PCR-3.1 AR or PCR3.1 expression vector. The cells were allowed to recover overnight and then treated with DMSO vehicle or 40 mM rosiglitazone for 24 h. Total RNA was extracted from treated cells using the Trizol reagent. qRT-PCR was then performed as described above to measure the level of FABP4 mRNA and 18S rRNA in each RNA sample.
Statistical analysis
Each experiment was performed at least three times and representative data are shown. For transient transfections and qRT-PCR experiments, One Way Analysis of Variance (ANOVA) was used to detect differences between control and treatment groups. These analyses were performed using the Sigma Stat 3.1 program (Systat Software Inc.). The standard for statistical significance was P < 0.05.
Results

Androgens decrease PPARg protein levels in AR-positive cell lines
Our laboratory has previously shown that PPARg protein levels vary across castration-resistant human prostate cancer cells. In these studies, we noted that the PC-3 cell line, which expresses very little if any AR, contained high levels of PPARg protein while low levels of PPARg were present in the AR positive C4-2 cells (Moss et al., 2010) . To determine whether the presence of AR influences PPARg expression, we first tested the ability of the AR agonist dihydrotestosterone (DHT) to modulate PPARg protein levels within the AR-positive C4-2 cells. DHT produced a concentration-dependent decrease in not only nuclear PPARg but also the total amount of PPARg protein within C4-2 cells (Fig. 1A) . The greatest reduction in PPARg levels was noted at DHT concentrations !1 nM (Fig. 1A) . This reduction was also time-dependent. Over the time frame examined, a reduction in PPARg protein levels was detected in C4-2 cells after 6 h of DHT treatment. Furthermore, PPARg levels remained low after 24 h of DHT exposure (Fig. 1B) . This reduction in PPARg protein levels was not unique to the C4-2 cell line. Nanomolar concentrations of DHT produced a similar decrease in PPARg protein in the ARpositive VCaP cells (Fig. 1C) .
Androgens reduce PPARg mRNA levels
One mechanism by which androgens could suppress PPARg protein levels is by changing the amount of PPARg mRNA present in the cell. To explore this possibility, we measured the effect of DHT on PPARg mRNA levels. We began these studies by defining the PPARg isoforms expressed within C4-2 and other prostate cancer cell lines. In mammals two isoforms of PPARg have been identified, PPARg1 and PPARg2. The isoforms differ in that PPARg2 contains an additional 30 amino acids at its N-terminus (Desvergne and Wahli, 1999) . Therefore, in these studies we used primers that could detect both PPARg isoforms (PPARg1 and PPARg2; total PPARg) as well as PPARg2-specific primers. In qRT-PCR experiments that involved primers against total PPARg, PPARg mRNA was detected in the C4-2, PC-3 and VCaP cells. However, very little if any PPARg was detected in experiments involving the PPARg2 specific primers (Fig. 2A) . These data suggest that PPARg1 is the dominant isoform expressed in C4-2, PC-3, and VCaP cells. Since the total PPARg primers were effective in detecting PPARg within our cell lines, we used those primers in subsequent qRT-PCR experiments.
We next explored the ability of DHT to alter PPARg mRNA levels within AR-positive cell lines. qRT-PCR revealed DHT produces a time-and concentration-dependent decrease in PPARg mRNA in C4-2 cells (Fig. 2B and C) . The nanomolar concentrations of DHT that reduced PPARg protein levels were also effective at suppressing PPARg mRNA levels. DHT at concentrations !1 nM lowered PPARg mRNA levels by approximately 40-50%. At very early time points (i.e., 3 h) DHT did not produce a dramatic change in PPARg mRNA levels. However, we did see a significant reduction in PPARg mRNA in C4-2 cells exposed to DHT for !9 h (Fig. 2C) . Nanomolar concentrations of DHT were also effective at reducing PPARg mRNA in the AR-positive VCaP prostate cancer cell line (Fig. 2D) . It therefore appears that the ability of DHT to suppress PPARg mRNA was not limited to C4-2 cells, but also occurs in other AR-containing human prostate cancer cell lines.
AR regulates PPARg expression and activity in C4-2 cells
To determine the importance of AR in DHT-mediated suppression of PPARg mRNA and protein, we performed a series of experiments involving the first generation AR antagonist bicalutamide and the second generation AR antagonist enzalutamide. In these experiments, C4-2 cells were pretreated with AR antagonists prior to the addition of 1 nM DHT. Both bicalutamide and enzalutamide blocked DHTinduced reductions in PPARg mRNA (Fig. 3A) . Furthermore, the ability of DHT to reduce PPARg protein was suppressed in C4-2 cells pretreated with either bicalutamide or enzalutamide (Fig. 3B) . These data suggest AR is required for DHTstimulated reductions in PPARg mRNA and protein.
To further characterize the role of AR in the regulation of PPARg, we examined how loss of AR influences PPARg protein levels and activity. In these studies we used an AR siRNA SMARTpool reagent to reduce wild type AR levels within the C4-2 cell line. siRNA-mediated knockdown of AR produced a two-fold increase in PPARg protein in C4-2 cells (Fig. 4A) . A PPRE3-luciferase reporter construct was then used to determine whether the function of PPARg might be influenced by AR levels. Luciferase-based reporter assays revealed knockdown of wild type AR protein in C4-2 cells increases basal PPARg transcriptional activity. In addition, the ability of the PPARg agonist rosiglitazone to activate PPARg was enhanced in C4-2 cells transfected with AR siRNA (Fig. 4B) . We next used [ 3 H]-thymidine incorporation assays to determine whether the presence of AR modulates the antiproliferative effects of rosiglitazone. Exposure to rosiglitazone did not alter the level of [ 3 H]-thymidine incorporation in C4-2 cells transfected with control siRNA. However, rosiglitazone did significantly reduce [ 3 H]-thymidine incorporation in C4-2 cells that had been transfected with AR siRNA (Fig. 4C) . These data suggest that reductions in AR expression enhance the ability of PPARg agonists to decrease cell proliferation. 
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In our studies, reductions in AR activity and expression increased both PPARg expression and activity. This observation led us to predict that other factors that lower AR expression and/or function would also alter PPARg in human prostate cancer cells. Previous studies have shown that MG132 and other proteasome inhibitors decrease AR transcriptional activity within human prostate cancer cells by interfering with AR nuclear translocation (Lin et al., 2002; Hu et al., 2015) . We therefore tested the effects of two proteasome inhibitors, MG132 and bortezomib, on PPARg protein in C4-2 cells. In CSS-containing media MG132 alone lowered the amount of AR protein present in whole cell lysates and increased basal PPARg levels. DHT increased the total amount of AR protein present within C4-2 cells both in the absence and presence of MG132. However, MG132 pretreatment blocked the ability of DHT to reduce PPARg levels in the C4-2 cell line (Fig. 5A) . Since MG132 reduces translocation of AR into the nucleus and increases cytoplasmic AR levels ( (Lin et al., 2002) and data not shown), we believe the decrease in intracellular PPARg levels produced by MG132 is due to MG132-mediated reductions in AR nuclear translocation and function. Similar changes in AR and PPARg levels were produced by the proteasome inhibitor bortezomib. In androgen-containing media, micromolar concentrations of bortezomib increased PPARg protein levels (Fig. 5B) . At these concentrations bortezomib also reduced nuclear AR protein levels. Bortezomib not only functions as a proteasome inhibitor but also inhibits activation of the NFkB signaling pathway. However, the NFkB inhibitor BMS 345541 did not increase PPARg levels within C4-2 cells (Fig. 5B) . Furthermore, siRNA-mediated knockdown of p65 NFkB did not alter the ability of DHT to suppress PPARg in C4-2 cells (Fig. 5C) . Therefore, our data suggest that bortezomib-induced increases in PPARg protein are primarily due to proteasomemediated alterations in AR expression and/or activity.
Overexpression of AR suppresses PPARg transcriptional activity in PC-3 cells
PC-3 cells express high amounts of PPARg protein and low, non-detectable levels of AR protein (Moss et al., 2010) . To determine whether an increase in wild type AR levels would alter PPARg within AR-null prostate cancer cells, we transfected PC-3 cells with the pCR3.1-AR expression construct. The amount of PPARg present in AR-positive PC-3 cells was comparable to that found in cells transfected with the empty vector pCR3.1 (Fig. 6A) . However, the addition of AR did alter PPARg function. The basal level of PPARg luciferase activity in PC-3 cells transfected with the empty vector pCR3.1 was significantly higher than that found in PC-3 cells that express wild type AR. In addition, the ability of rosiglitazone to activate the PPRE-luciferase reporter was reduced in AR-positive PC-3 cells (Fig. 6B) . The presence of wild type AR also decreased basal levels of the PPARg target gene adipocyte FABP (FABP4) and reduced rosiglitazone-induced increases in FABP4 mRNA (Fig. 6C ).
Discussion
Our laboratory and others have previously shown that ligandmediated activation of PPARg can regulate AR activity in human prostate cancer cells (Hisatake et al., 2000; Yang et al., 2007; Moss et al., 2010) . In this study we demonstrate the expression of PPARg can be suppressed by activation of AR. Physiological concentrations of the AR agonist DHT reduced PPARg mRNA and protein levels within the castrationresistant C4-2 and VCaP cell lines. Furthermore, inhibition or knockdown of AR increases PPARg expression and activity within the AR-positive C4-2 cells. Taken together, these data indicate there is a bidirectional crosstalk between the PPARg and AR signaling pathways. Of the two isoforms of PPARg protein that exist in mammalian cells, PPARg2 is primarily expressed within adipose tissue while PPARg1 is present in multiple tissues including the prostate. While work by R. Singh et al. has shown that similar androgen concentrations reduce PPARg2 expression in mouse adipocytes (Singh et al., 2006) , ours is the first report to show androgens via AR also control PPARg activity and expression in human prostate cancer cells that predominantly express PPARg1. Our data suggest that androgens reduce expression of both PPARg isoforms and, as a result, have the potential to influence PPARg expression in the prostate and several other organ systems.
This study has primarily focused on interactions between the AR and PPARg signaling pathways in prostate cancer cells. It is also possible that crosstalk between these two pathways occurs within the normal prostate. Within the normal prostate AR is expressed in the stroma and luminal epithelial cells (Nieto et al., 2014) . PPARg has also been detected within normal prostatic epithelial cells, although multiple reports suggest the amount of PPARg present in normal and benign prostate cells and tissues is lower than that found in prostate cancers (Nwankwo and Robbins, 2001; Subbarayan et al., 2004; Nakamura et al., 2009; Rogenhofer et al., 2012) . To our knowledge, there are no studies that have directly examined the regulation of PPARg by AR within normal prostatic tissues. However D. Strand et al. have explored the regulation of AR signaling by PPARg. Their studies revealed that the addition of PPARg1 to mouse prostatic epithelial cells lacking PPARg (mPrE-gKO cells) resulted in a decrease in AR transcriptional activity, while restoration of PPARg2 increased DHT-induced AR activation (Strand et al., 2012) . Therefore PPARg may influence the function of AR in normal prostatic epithelial cells in an isoform-specific manner.
We believe that in the AR-positive C4-2 cells, AR-induced reductions in PPARg activity are due in part to reductions in PPARg protein. Increasing AR levels in the AR-null PC-3 cells was not enough to stimulate a decrease in PPARg, as AR overexpression in the AR-null PC-3 cells produced a minimal effect on PPARg protein levels. However, this elevation reduced the ability of PPARg ligands to induce transcription in the PC-3 cell line. These data would suggest that AR may be able to suppress PPARg transcriptional activity via a mechanism that does not require reductions in PPARg protein. In addition to receptor protein levels, the transcriptional activity of nuclear receptors is influenced by the recruitment of coactivators or corepressors. Coactivators such as SRC-1, TIF-2, and CBP have been shown to enhance the activity of both PPARg and AR (DiRenzo et al., 1997; Hong et al., 1997; Ding et al., 1998; Fronsdal et al., 1998; Chen et al., 2000; . Furthermore, the corepressor NCoR reduces the transcriptional activity of each receptor. NCoR has been shown to inhibit AR activity in human prostate cancer cells and other cell types (Cheng et al., 2002; Hodgson et al., 2005; Yoon and Wong, 2006; Godoy et al., 2012) , while it promotes phosphorylation of PPARg at Ser 273 and suppresses PPARg activation within adipocytes (Yu et al., 2005; Li et al., 2011) . The elevated level of NCoR in PC-3 cells has also been suggested to inhibit PPARg activity and reduce responsiveness to PPARg agonists (Battaglia et al., 2010) . It is possible that AR activation alters the availability of coactivators and/or corepressors, and ultimately reduces the pool of coregulators needed for efficient PPARg-mediated transcription. As a result, any increase in the amount of active AR within the cell produces a net decrease in PPARg function. However, to confirm that AR can alter PPARg signaling without significant alterations in PPARg protein additional experiments need to be performed in other AR negative prostate cancer cells that express functional PPARg.
While our data demonstrate AR suppresses the expression and activity of PPARg in human prostate cancer cells, the consequences of this decrease in PPARg activity are not fully understood. Data from [
3 H]-thymidine incorporation studies suggest that the presence of AR interferes with the ability of PPARg agonists to inhibit prostate cancer proliferation. Our data also indicate that AR-driven reductions in PPARg function influence the expression of gene products within human prostate cancer cells. In our study, the presence of AR blocked the ability of PPARg to stimulate expression of adipocyte FABP/FABP4. FABP4 is a protein present within the cytoplasm and circulation that regulates fatty acid transport. Intracellular FABP has also been linked to alterations in prostate cell survival and proliferation. De Santis et al. showed that overexpression Ã P < 0.05 compared to the control (DHT-, Bic-, ENZ-) group. (B) C4-2 cells were first pretreated with either DMSO vehicle, 10 mM bicalutamide, or 10 mM enzalutamide. The cells were next exposed to EtOH or 1 nM DHT for 24 h. Whole cell extracts were prepared from treated cells. Western blot analysis was then performed to measure the level of AR, PPARg and actin protein in each extract.
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A N D R O G E N R E C E P T O R S U P P R E S S E S P P A R g of FABP4 induced apoptosis within the DU-145 prostate cancer cell line (De Santis et al., 2004) . Furthermore, concentrations of bisphenol A that stimulate proliferation within the ventral prostate also decreased expression of FABP4 (Hotamisligil and Bernlohr, 2015) . It is therefore possible that AR promotes growth and survival of human prostate cancer cells in part by controlling PPARg-mediated increases in FABP4. PPARg activation has also been shown to induce expression of lipoprotein lipase (Lefebvre et al., 1997) and GLUT4 (Dana et al., 2001 ) and decrease leptin and TNF-a levels (Spiegelman, 1998) . By controlling the expression of these and other gene products, PPARg functions as a key regulator of glucose metabolism, lipid metabolism and insulin sensitivity Tontonoz and Spiegelman, 2008) . A recent ChIP-seq study by CE Massie et al. has shown that within human prostate cancer cell lines AR also regulates metabolic gene products. The AR target genes identified within their study include CAMKK2, GLUT1, hexokinase I and II, as well as other genes that regulate metabolism of glucose, lipids and amino acids (Massie et al., 2011) . Our work suggests that along with above listed direct gene targets, AR may indirectly control expression of genes that regulate prostate cancer metabolism by suppressing PPARg. However, additional studies are required to better understand how AR-driven reductions in PPARg function influence growth, proliferation and metabolism of prostate cancer cells.
In this study, we have primarily focused on the effect of the full length, 110 kDa form of the AR on PPARg expression and function. However in addition to the full length AR, constitutively active N-terminal AR variants that lack the C-terminal ligand binding domain have been detected in human prostate cancer cell lines and tumor samples (van der Steen et al., 2013) . Data from transgenic mouse studies indicate the presence of AR variants such as AR3/ARv-7 and ARv567es is linked to the development of prostate cancer as well as the progression to castration-resistant prostate cancer Sun et al., 2014) . The development of resistance to newer AR antagonists such as enzalutamide has also been associated with elevated expression of AR variants in castration-resistant prostate cancer cells (Li et al., 2013; Nadiminty et al., 2013) . Like the wild type AR, the AR variants regulate expression of several classic AR target genes such as PSA, TMPRSS2, and Nkx3.1 (Hu et al., 2009; Chan et al., 2012) . However, some studies suggest AR variants may also regulate expression of unique gene targets within human tissues independent of full length AR (Guo et al., 2009; Hu et al., 2009) . Studies are currently underway in our laboratory to assess whether ARv7 and other AR variants influence PPARg expression and function in human prostate cancers.
In conclusion, AR normally functions to inhibit PPARg expression and transcriptional activity within human prostate cancer cells. AR continues to be a primary therapeutic target for both castration-sensitive as well as castration-resistant prostate cancer. ADT is commonly used to reduce AR signaling in patients with advanced, metastatic prostate cancer. Furthermore, newer drugs that inhibit the AR signaling pathway have been approved by the Federal Drug Administration to treat metastatic, castration-resistant prostate cancer. Abiraterone acetate, which blocks intratumoral and extratumoral androgen synthesis, and the more potent AR antagonist enzalutamide have been shown to enhance survival of prostate cancer patients that have developed castration-resistant forms of prostate cancer. Our study would suggest that these and other therapeutic strategies that interfere with AR activity, whether they are competitive inhibitors of AR or other compounds that block androgen synthesis or AR nuclear localization, would ultimately result in increased PPARg levels within prostate tumor cells. Consequently, strategies that reduce AR function could be used to increase the net amount of PPARg and anti-tumor effects of PPARg agonists in prostate cancer cells. Furthermore, PPARg expression and/or activity could serve as useful measure of AR function within human prostate cancers. In parts B and C, each bar represents the mean AESEM of three wells. Ã P < 0.05 compared to the PCR3.1, DMSO group.
ÃÃ P < 0.05 compared to the PCR-AR, DMSO group.
